• YZ462 and MRSA: Promise, Evidence, and Limits

  2026-10-13

  A source-grounded overview of a 2025 study reporting that YZ462 damages MRSA membranes, affects biofilms, and showed activity in animal models, while emphasizing the study’s evidentiary limits and the gap between preclinical findings and clinical relevance.

• YZ462 and the Evidence for Anti-MRSA Activity

  2026-10-13

  Guo et al. report that YZ462, a heteroaromatic-aryl compound, showed activity against methicillin-resistant Staphylococcus aureus in cellular, biofilm and animal-model studies. The authors link its effects to membrane disruption, increased permeability, reactive oxygen species and interaction with cardiolipin. These findings support YZ462 as a preclinical lead, but they do not establish clinical efficacy, human safety or applicability across the diversity of MRSA infections.

• Isoprinosine and the CLCC1 Herpesvirus Finding

  2026-10-12

  A preprint identifies CLCC1 as a host factor associated with herpesvirus nuclear egress, but the finding does not establish that Isoprinosine or inosine pranobex targets CLCC1, alters membrane fusion, or provides clinical benefit against herpesvirus infection.

• SNS-032 and SARS-CoV-2 Host-Factor Evidence

  2026-10-12

  Kerr et al. identified vesicle-mediated transport, including Rab11a-linked cargo delivery, as a SARS-CoV-2 release-associated pathway and reported inhibition with CDKI-73. These findings should not be treated as evidence that SNS-032 was tested or that its cancer-model pharmacology translates into antiviral activity.

• What 5′ UTR Comparisons Really Show

  2026-10-11

  A 2026 comparison reports that bovine β-globin 5′ UTR supported stronger translation of several reporter and antigenic proteins than the other tested UTRs. The finding is relevant to mRNA construct design in a narrow experimental context, but it does not establish that EZ Cap™ Mouse IL-12 mRNA (m1Ψ) has superior expression, cytokine activity, delivery, or therapeutic performance.

• Recombinant Human Oncostatin M in HCC Adaptation

  2026-10-10

  Recombinant Human Oncostatin M offers a defined cytokine input for studying how extracellular signaling may intersect with ALKBH5-driven adaptation in hepatocellular carcinoma. This evidence-focused article separates established product biology from emerging hypotheses based on a 2026 sorafenib-resistance study.

• SDF-1beta (CXCL12) in Brucella Host-Cell Biology

  2026-10-09

  SDF-1beta (CXCL12), human recombinant, offers a defined way to examine chemokine context around host-cell phenotypes. This article interprets the 2026 Brucella CRISPR screen through a CXCL12-centered lens while separating demonstrated mechanisms from testable hypotheses.

• AY 9944 Dihydrochloride: Evidence and Limits

  2026-10-09

  AY 9944 dihydrochloride is a research compound used to study DHCR7, cholesterol biosynthesis, and 7-dehydrocholesterol biology. This overview compares supplier-described pharmacology with a 2026 grass carp gene-disruption study linking dhcr7 deficiency to improved resistance against grass carp reovirus, while separating genetic evidence from unproven claims about chemical inhibition, mammalian immunity, or therapeutic use.

• Dimethyloxalylglycine (DMOG) Overview

  2026-10-08

  Dimethyloxalylglycine (DMOG; SKU A4506) is described by APExBIO as a cell-permeable competitive PHD inhibitor for conceptual studies of HIF stabilization and hypoxia-related signaling. No matched paper evidence is available for this product entry.

• Pomalidomide (CC-4047) in Myeloma Research

  2026-10-08

  This source-grounded overview examines Pomalidomide, also known as CC-4047, in the context of multiple myeloma and broader hematological malignancy research. It distinguishes findings from the primary multiple myeloma cell-line literature from claims reported in a supplier description, emphasizing model selection, tumor microenvironment modulation, evidence strength, and applicability limits.

• Lactate, HMGB1, and Exosomal Signaling in Sepsis

  2026-10-07

  Yang et al. identify a mechanistic link between elevated lactate and HMGB1 release during polymicrobial sepsis. The study connects lactate uptake and GPR81-associated signaling with HMGB1 lactylation, acetylation, exosomal export, and increased endothelial permeability, while also defining important boundaries for interpretation.

• IL-7, Human Recombinant: An ER Biology Lens

  2026-10-07

  IL-7, human recombinant provides a useful immunology context for interpreting ER proteostasis research. This article examines how SARS-CoV-2 PLpro reshapes ER-associated degradation and explains where IL-7 can inform, but not replace, mechanistic evidence.

• Pomalidomide (CC-4047) in Myeloma Research

  2026-10-06

  Pomalidomide, also known as CC-4047, is an immunomodulatory compound studied in multiple myeloma and other hematological malignancy research. This overview separates established mechanism, cell-line genomics, supplier-reported findings, conceptual applications, and evidence limitations, with particular attention to tumor microenvironment modulation, drug resistance, and erythroid progenitor cell differentiation.

• CREATE: RNA-Based Gene Editing Without DSBs

  2026-10-06

  The CREATE platform combines CRISPR/Cas9 targeting with LINE-1-mediated reverse transcription to insert an RNA-encoded payload without relying on a CRISPR-induced double-strand break or DNA donor template. In the reference study, CREATE enabled insertion of a 1.1 kb promoter–GFP cassette in human cell lines and primary T cells, while reported off-target assessment found no observed unintended events within the study scope.

• Triptolide (PG490): From Transcription to Translation

  2026-10-05

  Triptolide, also known as PG490, offers translational researchers a mechanistic lens on transcriptional stress, immune regulation, tumor invasion, and inflammatory tissue injury. This perspective connects established product intelligence with a 2025 acute pancreatitis study while defining evidence boundaries.

8536 records 1/570 page Next 12345 下5页 Last page